Average Co-Inventor Count = 9.48
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Merck Sharp + Dohme Corp. (12 from 2,405 patents)
2. Valo Health, Inc. (5 from 29 patents)
3. Vertex Pharmaceuticals, Inc. (3 from 1,149 patents)
4. Valo Early Discovery, Inc. (3 from 15 patents)
5. Forma Therapeutics, Inc. (2 from 125 patents)
6. Merck Canada Inc. (2 from 40 patents)
7. Merck + Co., Inc. (1 from 4,770 patents)
8. Tango Therapeutics, Inc. (1 from 8 patents)
27 patents:
1. 12252490 - Inhibiting deubiquitinase USP25 and USP28
2. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors
3. 12043607 - HDAC inhibitors and therapeutic use thereof
4. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
5. 11524966 - Carboxamides as ubiquitin-specific protease inhibitors
6. 11325917 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
7. 10934299 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
8. 10913753 - Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
9. 10889592 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
10. 10377760 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
11. 10072025 - Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors
12. 10059705 - Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
13. 9957264 - Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
14. 9957265 - N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors
15. 9902728 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors